Category Archives: Topics

Will 2seventy’s Novel Pipeline Assets be Innovative Enough? 2seventy’s Research Deep Dive Investor Event Summary

On September 21 – 22, 2seventy bio (bluebird bio’s oncology business) held two Research Deep Dive sessions (Day 1 presentation / Day 2 presentation) detailing their novel pipeline assets across liquid and solid tumors. Below, Celltelligence provides insights on how 2seventy’s novel assets compare with key competitors, while discussing innovative manufacturing options for 2seventy.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Carisma’s CT-0508 (HER2 CAR-Macrophage) Receives Fast Track Designation From the FDA

On Wednesday, September 22, Carisma announced (press release) that the FDA has granted Fast Track designation to CT-0508 (HER2-targeting CAR-Macrophage) for HER2-overexpressing solid tumors. Below, Celltelligence provides insights on how CT-0508 could benefit from Fast Track designation, while discussing the potential advantages of CAR-Macrophages (CAR-M).

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Two Novel CAR-Ts for Solid Tumors Demonstrate Promising Efficacy / Activity; Are CAR-Ts More Advantageous Than Bispecific Antibodies? ESMO 2021 Day 4 – 6

On the last three days of ESMO 2021, two key presentations highlighting clinical and pre-clinical data for CAR-T candidates treating solid tumors were presented. Additionally, a Controversy Session was held discussing the key benefits and challenges for bispecific antibodies and CAR-Ts.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Allogene Appoints Jae Park to Their Scientific Advisory Board

On Monday, September 20, Allogene announced (press release) that Jae Park has been appointed to their Scientific Advisory Board (SAB). Below, Celltelligence provides insights on how Allogene could leverage Park’s clinical experience to advance novel pipeline products.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

TCR2 on Track to Identify Gavo-cel’s (Mesothelin TRuC-T) RP2D by YE 2021; Will Checkpoint Inhibitors Improve Gavo-cel’s Efficacy? ESMO 2021 Day 2

On Friday, September 17, TCR2 Tx held an investor call (press release / presentation) highlighting updated clinical data presented at ESMO from gavo-cel’s (TC-210; autologous mesothelin TRuC-T) Ph1/2 trial in advanced mesothelin-expressing cancers. Below, Celltelligence provides insights on TCR2’s approach to find gavo-cel’s RP2D, and how combining a PD1 inhibitor with gavo-cel could improve the TRuC-T’s efficacy profile, while discussing gavo-cel’s potential expansion into other indications.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

GSK Explores Better Patient Selection Methods for Lete-cel; Could 2seventy bio Nominate Medigene’s PRAME TCR-T as Their Second Target? Adaptimmune Presents Preclinical Data from ADP-A2M4CD8; No Updated Preclinical Results from Carisma; Tecartus Absent from CHMP Highlights; ESMO 2021 Day 1&2

On the first two days of ESMO 2021, four key pre-clinical and clinical presentations from GSK, Medigene, Adaptimmune, and Carisma were presented. On Friday, September 17, the CHMP highlights for September were released. Of note, no updates from Tecartus’s Type II variation for r/r adult ALL were observed. Below, Celltelligence provides insights and context for each presentation, while providing likely EU approval timelines for Tecartus.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Autolus Announces Progress with New UK Manufacturing Site

On Thursday, September 16, Autolus announced (press release) planning approval for a new manufacturing facility in Stevenage, UK. Of note, the manufacturing facility will initially provide ~2,000 doses a year of obe-cel (CD19 CAR-T; formerly AUTO1). Below, Celltelligence provides insights into Autolus’s manufacturing strategy, while discussing whether the new facility could enhance Autolus’s potential to be acquired.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Autolus Appoints John Johnson to Their Board of Directors

On Wednesday, September 15, Autolus announced (press release) John Johnson’s appointment as non-executive chairman of their Board of Directors. Additionally, Martin Murphy, who previously served as chairman, will continue to serve as a non-executive board member. Below, Celltelligence provides insights on Autolus’s leadership strategy to prepare for obe-cel’s (CD19 CAR-T, formerly AUTO1) commercial launch, while commenting on the potential acquisition of Autolus.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Thoughts on Novartis’s Ph3 BELINDA Trial Failure; Will Novartis Continue Pursuing Kymriah in the 2L DLBCL Setting?

Recently, Novartis reported (press release) that their Ph3 BELINDA study evaluating Kymriah (CD19 CAR-T) in 2L NHL did not meet its primary endpoint (EFS) compared to the standard of care (SoC). Below, Celltelligence provides insights on how Novartis’s trial design could have potentially contributed to BELINDA’s failure, while discussing alternative approaches that Novartis may take to stay in the 2L DLBCL setting.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Adaptimmune’s ADP-A2M4CD8 Has a Best Response With Ovarian Cancer Patients; Legend’s LB1901 Ph1 Trial Initiated in the US

On Monday, September 13, Adaptimmune reported (press release / presentation) updated data from ADP-A2M4CD8’s (MAGE-A4 SPEAR-T) Ph1 SURPASS study for multiple solid tumors. Of note, Adaptimmune highlighted ADP-A2M4CD8’s safety profile and compared initial efficacy data to the company’s first-generation MAGE-A4 SPEAR-T therapy (afami-cel; formerly ADP-A2M4). On the same day, Legend announced (press release) the start of LB1901’s (CD4 CAR-T) Ph1 trial in the US for r/r peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma (CTCL). Below, Celltelligence provides insights on which indications Adaptimmune could prioritize, while discussing Legend’s clinical development of LB1901 in the TCL setting.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.